Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Merck AG initially bought US rights from Th

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Nov 21, 2022 5:25pm

76 Views

Post# 35116936

RE:Merck AG initially bought US rights from Th

Wow! You're memory is long. What was teh difference in this Ph. 3 trial versus what they are attempting to do today?

Biobob wrote:

October 29, 2008

Merck KGaA finds value in Theratechnologies

Amy Brown

Merck KGaA has come to the rescue of Theratechnologies, buying US rights to Tesamorelin, in phase III trials as a treatment for excess abdominal fat in HIV patients with lipodystrophy, in a deal worth up to $215m.

Phase III data on the product released so far has been disappointing, leading to predictions that the company would struggle to sign up a top tier pharmaceutical company; a prediction that appears to have come true (Tesamorelin data reduces options for Theratechnologies, June 23, 2008). Even so, the underwhelming response from investors was surprising, with the stock edging just 7% higher to C$2.35 in early trade.